Biofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results
Biofrontera AG (NASDAQ: BFRA), a biopharmaceutical company based in Germany, will announce its first quarter 2020 unaudited financial results on May 19, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biofrontera AG (NASDAQ: BFRA), a biopharmaceutical company based in Germany, will announce its first quarter 2020 unaudited financial results on May 19, 2020. Shareholders and investors are invited to join conference calls on May 20, 2020, with sessions in both German and English. The company specializes in dermatological drugs and medical cosmetics, with notable products like Ameluz® and Xepi™. Biofrontera is recognized for being the first German founder-led pharmaceutical firm to gain both European and US drug approvals.
Details
News Market Reaction – BFRA
The recorded move for BFRA in the trading session of this news was +6.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leverkusen, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its unaudited financial results for the first quarter 2020 on Tuesday, May 19, 2020.
Conference calls for shareholders and interested investors will be held on Wednesday, May 20, 2020, at the following times:
In German, May 20, 2020 at 08:00 am CEST (2:00 am EST)
Dial-in number Germany: +49 69201744220
Conference code: 50182305#
In English, May 20, 2020 at 2:00 pm CEST (8:00 am EST)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Conference code: 70870259#
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
-End-
| For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer | +49 (0) 214 87 63 2 0 ir@biofrontera.com |
| IR UK: Seton Services Toni Vallen | +44 (0) 207 229 0805 |
| IR and PR US: The Ruth Group IR: Tram Bui PR: Kirsten Thomas | +1 646-536-7035 +1 508-280-6592 |
About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.